Petra Duda, M.D., Ph.D. was appointed Chief Medical Officer of Inozyme Pharma in May 2025, bringing more than two decades of global leadership in clinical development, medical affairs, and regulatory strategy, with deep expertise in rare and ultra-rare diseases.
Dr. Duda joined Inozyme in November 2024 and most recently served as Global Development Lead at UCB, where she oversaw the Zilbrysq® (zilucoplan) program and led it through global regulatory approvals for the treatment of generalized myasthenia gravis. She joined UCB through its acquisition of Ra Pharmaceuticals, where she led clinical development for a portfolio of complement pathway inhibitors.
Earlier in her career, Dr. Duda held senior roles at Sarepta Therapeutics, where she played a pivotal role in the development and approval of Exondys 51® for Duchenne muscular dystrophy, and at Biogen Idec, where she led neurology development programs. She also held positions in medical affairs and drug safety at Boehringer Ingelheim.
Dr. Duda is board certified in both Neurology and Pharmaceutical Medicine. She earned her M.D. and Ph.D. in molecular biology and biochemistry from the University of Bern.